Markets:

Overview

News

Currencies

International

Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

73.61 -0.39 (-0.52%)

Streaming Delayed Price Updated: 10:45 AM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. ↗

November 21, 2024

In the world of growth stocks, NYSE:HAE shines as a value proposition.

Via Chartmill

Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings) ↗

November 08, 2024

Via Benzinga

NYSE:HAE is not too expensive for the growth it is showing. ↗

October 31, 2024

While growth is established for NYSE:HAE, the stock's valuation remains reasonable.

Via Chartmill

Despite its growth, NYSE:HAE remains within the realm of affordability. ↗

October 10, 2024

HAEMONETICS CORP/MASS (NYSE:HAE), a growth stock which is not overvalued.

Via Chartmill

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

September 24, 2024

From Aligos Therapeutics

Via GlobeNewswire

What Analysts Are Saying About Haemonetics Stock ↗

September 10, 2024

Via Benzinga

Investors should take note of NYSE:HAE, a growth stock that remains attractively priced. ↗

August 28, 2024

Looking for growth without the hefty price tag? Consider NYSE:HAE.

Via Chartmill

Analyst Expectations For Haemonetics's Future ↗

August 22, 2024

Via Benzinga

NYSE:HAE stands out as a growth opportunity that won't break the bank. ↗

September 18, 2024

Investors should take note ofHAEMONETICS CORP/MASS (NYSE:HAE), a growth stock that remains attractively priced.

Via Chartmill

Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗

August 16, 2024

Via Benzinga

Investors should take note of NYSE:HAE, a growth stock that remains attractively priced. ↗

August 06, 2024

Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSE:HAE).

Via Chartmill

Sotera Health Appoints Christopher Simon to the Board of Directors

August 01, 2024

From Sotera Health Services, LLC

Via GlobeNewswire

NYSE:HAE stands out as a growth opportunity that won't break the bank. ↗

July 16, 2024

NYSE:HAE is not too expensive for the growth it is showing.

Via Chartmill

Looking for growth without the hefty price tag? Consider NYSE:HAE. ↗

June 25, 2024

HAEMONETICS CORP/MASS (NYSE:HAE) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NYSE:HAE, a growth stock which is not overvalued. ↗

June 03, 2024

Despite its growth, HAEMONETICS CORP/MASS (NYSE:HAE) remains within the realm of affordability.

Via Chartmill

4 Analysts Assess Haemonetics: What You Need To Know ↗

May 10, 2024

Via Benzinga

Earnings Scheduled For February 8, 2024 ↗

February 08, 2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.

Via Benzinga

Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst ↗

June 12, 2024

Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112.

Via Benzinga

This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

June 12, 2024

Via Benzinga

These 3 Companies Boast Bright Outlooks ↗

June 05, 2024

Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 21, 2024

Via Benzinga

HAE Stock Earnings: Haemonetics Beats EPS, Beats Revenue for Q4 2024 ↗

May 09, 2024

HAE stock results show that Haemonetics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024.

Via InvestorPlace

Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing? ↗

October 09, 2023

Why the quality investor may take a look at HAEMONETICS CORP/MASS (NYSE:HAE).

Via Chartmill

Exploring NYSE:HAE's quality characteristics. ↗

September 05, 2023

Should you consider HAEMONETICS CORP/MASS (NYSE:HAE) for quality investing?

Via Chartmill

Should you consider NYSE:HAE for quality investing? ↗

August 10, 2023

HAEMONETICS CORP/MASS (NYSE:HAE) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. ↗

April 05, 2024

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.

Via Chartmill

Intuitive Surgical Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark ↗

November 17, 2023

Intuitive Surgical stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 74 to 85.

Via Investor's Business Daily

Intuitive Surgical Stock Rating Climbs As Sales, Profits Rise ↗

October 16, 2023

Intuitive Surgical stock got an IBD rating upgrade Monday. It edged up 0.37% to 274.16, its second day in a row of rising share price.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

October 10, 2023

Via Benzinga

Intuitive Surgical Stock Nearly Doubles; Gets Rating Upgrade ↗

September 26, 2023

Intuitive Surgical stock dipped to an intraday low 180.07 in October last year as the bear market ended, then shot up to 358.07 on July 19.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.